Jaguar health subsidiary announces completion of additional preclinical study of lechlemer (np-300), the company's human drug product candidate for diarrhea relief from cholera and other acute infectious diarrhea

In support of planned investigational new drug application for lechlemer, napo pharmaceuticals, jaguar's wholly owned subsidiary, received comprehensive animal toxicity preclinical services supported by the national institute of allergy and infectious diseases for four studies san francisco, ca / accesswire / august 17, 2021 / napo pharmaceuticals, inc. ("napo"), the wholly-owned subsidiary of jaguar health, inc. (nasdaq:jagx) ("jaguar" or the "company"), announced today the completion of an additional preclinical toxicology study intended to support continued development of np-300 (lechlemer) for the symptomatic relief of diarrhea from cholera and other infectious diarrheal conditions. the study findings support the investigational new drug (ind) application napo plans to file for lechlemer for this indication in the first half of 2022.
JAGX Ratings Summary
JAGX Quant Ranking